McDermott Represents MERCK GHI in its investment in M2GEN
SOURCE: McDermott Will & Emery
NEW YORK, March 23, 2021 /mwe.com/ — New York: International law firm McDermott Will & Emery represented Merck Global Health Innovation Fund (Merck GHI), a corporate healthcare venture capital fund, in its investment to recapitalize M2GEN, a leading oncology data and informatics platform focused on transforming cancer care. Clayton, Dubilier & Rice (CD&R) served as the lead investor alongside Merck GHI and McKesson Ventures. The financial terms of the transaction were not disclosed.
The transaction closed on March 17, 2021.
Todd Finger of McDermott Will & Emery acted as legal advisor to Merck GHI.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.